AnaptysBio, Inc. (ANAB) financial statements and ratios from SEC XBRL: revenue $0.2B (TTM), net margin -5.6%, revenue growth 157.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $234.60M |
| Revenue (TTM) | $0.2B |
| Net Margin | -5.6% |
| Operating Margin (TTM) | 17.6% |
| Revenue Growth (YoY) | 157.0% |
| EPS Growth (YoY) | -91.0% |
| FCF Growth (YoY) | -114.5% |
| Price / Book | 131.78 |
| Price / Sales | 11.06 |
| FCF Yield | -9.9% |
| Altman Z-Score | 2.22 (grey) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ANAB overview · ANAB earnings · ANAB KPIs · ANAB documents · ANAB ownership · ANAB peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.